Information about the Aspen Ideas Festival is here. I am scheduled for a session, The American Wellness Paradox, currently scheduled from 11:00-11:50 a.m., at the East Lawn Tent. This will be a discussion with senior HHS policy advisor, Calley Means. Here’s the blurb on it: “Americans are spending more than ever on healthcare, supplements, wellness trends, and “clean eating,” yet rates of chronic disease and metabolic illness continue to climb. As skepticism fuels the rise of movements like MAHA, debates over what Americans should eat have become deeply cultural, political, and economic. Two influential voices with sharply different perspectives on nutrition and food science explore how food systems, farming practices, consumer culture, and the wellness industry collided to create one of the defining public health debates of our time.”
How GLP-1 drugs are likely to affect the food industry
I am fortunate to be on the mailing list for Nicholas Fereday’s always-worth-reading Rabobank’s RaboResearch. This one is especially worth sharing: Talking Points: Anti-obesity medications—Will the food industry be the biggest loser?
It has been oer a year since the food industry finally woke up to the threats and opportunities of the new class of Anti-Obesity Medications (AOMs) such as Ozempic, Wegovy and Zepbound. And gosh, what a lot has happened since then. Chiefly, both the demand and supply of these drugs have exceeded all expectations and the momentum driving the market suggests they are highly likely to become a permanent feature of the food landscape. Doubly so as scientists keep finding further benefits from taking them – the weight loss effects of these drugs might ultimately prove to be their least remarkable feature. But for now, the impact of these drugs on the food industry is real. The challenge for the food industry is to figure out how to respond to that and unlock some of the opportunities these drugs create. Here are three points to consider:
1. The AOM market is much bigger and growing much faster than anticipated.
2. There are good reasons to believe demand has strong momentum.
3. Users of AOMs eat less and differently, providing a useful roadmap for food companies.
